209 related articles for article (PubMed ID: 36093297)
1. Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma.
LeBlanc FR; Hasanali ZS; Stuart A; Shimko S; Sharma K; Leshchenko VV; Parekh S; Fu H; Zhang Y; Martin MM; Kester M; Fox T; Liao J; Loughran TP; Evans J; Pu JJ; Spurgeon SE; Aladjem MI; Epner EM
Oncotarget; 2022; 13():986-1002. PubMed ID: 36093297
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
3. Phase 1-2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma.
Spurgeon SE; Sharma K; Claxton DF; Ehmann C; Pu J; Shimko S; Stewart A; Subbiah N; Palmbach G; LeBlanc F; Latour E; Chen Y; Mori M; Hasanali Z; Epner EM
Br J Haematol; 2019 Sep; 186(6):845-854. PubMed ID: 31177537
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.
Puvvada SD; Guillen-Rodriguez J; Kumar A; Inclán L; Heard K; Rivera XI; Anwer F; Schatz JH; Mahadevan D; Persky DO
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):58-64. PubMed ID: 29056470
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody.
Maeda T; Yamada Y; Tawara M; Yamasaki R; Yakata Y; Tsutsumi C; Onimaru Y; Kamihira S; Tomonaga M
Int J Hematol; 2001 Jul; 74(1):70-5. PubMed ID: 11530808
[TBL] [Abstract][Full Text] [Related]
6. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
7. The epigenetics of mantle cell lymphoma.
Yu M; Epner E
Curr Treat Options Oncol; 2007 Oct; 8(5):375-81. PubMed ID: 18214689
[TBL] [Abstract][Full Text] [Related]
8. Treatment options for mantle cell lymphoma.
Smolewski P; Witkowska M; Robak T
Expert Opin Pharmacother; 2015; 16(16):2497-507. PubMed ID: 26360791
[TBL] [Abstract][Full Text] [Related]
9. A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Ogura M; Ando K; Suzuki T; Ishizawa K; Oh SY; Itoh K; Yamamoto K; Au WY; Tien HF; Matsuno Y; Terauchi T; Yamamoto K; Mori M; Tanaka Y; Shimamoto T; Tobinai K; Kim WS
Br J Haematol; 2014 Jun; 165(6):768-76. PubMed ID: 24617454
[TBL] [Abstract][Full Text] [Related]
10. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma.
Spurgeon SE; Pindyck T; Okada C; Chen Y; Chen Z; Mater E; Abbi K; Epner EM
Leuk Lymphoma; 2011 Aug; 52(8):1488-94. PubMed ID: 21623691
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P
Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933
[TBL] [Abstract][Full Text] [Related]
12. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study.
Behr TM; Griesinger F; Riggert J; Gratz S; Béhé M; Kaufmann CC; Wörmann B; Brittinger G; Becker W
Cancer; 2002 Feb; 94(4 Suppl):1363-72. PubMed ID: 11877767
[TBL] [Abstract][Full Text] [Related]
13. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
Robak T; Smolewski P; Cebula B; Szmigielska-Kaplon A; Chojnowski K; Blonski JZ
Cancer; 2006 Oct; 107(7):1542-50. PubMed ID: 16948126
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
[TBL] [Abstract][Full Text] [Related]
16. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma.
Inwards DJ; Fishkin PA; LaPlant BR; Drake MT; Kurtin PJ; Nikcevich DA; Wender DB; Lair BS; Witzig TE
Ann Oncol; 2014 Oct; 25(10):2020-2024. PubMed ID: 25057177
[TBL] [Abstract][Full Text] [Related]
19. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
Foran JM; Rohatiner AZ; Cunningham D; Popescu RA; Solal-Celigny P; Ghielmini M; Coiffier B; Johnson PW; Gisselbrecht C; Reyes F; Radford JA; Bessell EM; Souleau B; Benzohra A; Lister TA
J Clin Oncol; 2000 Jan; 18(2):317-24. PubMed ID: 10637245
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic targeting in mantle cell lymphoma.
Dunleavy K
Br J Haematol; 2019 Sep; 186(6):805-806. PubMed ID: 31489625
[No Abstract] [Full Text] [Related]
[Next] [New Search]
